In 106 patients with mild (grade 1–2) immune checkpoint inhibitor pneumonitis, a 3-week corticosteroid taper failed non-inferiority to a 6-week taper: 8-week treatment success 66.7% vs 85.2%. Grade ≥3 adverse events were 12% vs 24%; survival was similar.
RCTn = 106
Fujimoto et al. Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial